摘要
目的:探讨伏格列波糖联合维格列汀治疗2型糖尿病的疗效及安全性。方法:选取2015年6月—2016年6月南阳市第一人民医院收治的2型糖尿病患者96例作为研究对象,以抽签法将患者随机分为观察组和对照组,每组48例。对照组患者给予维格列汀治疗,观察组患者在对照组的基础上加用伏格列波糖治疗。比较两组患者血糖及生化指标、不良反应发生情况。结果:治疗后,两组患者空腹血糖、餐后2 h血糖、C反应蛋白、糖化血红蛋白水平明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05);治疗后,两组患者空腹血胰岛素与餐后2 h胰岛素明显高于治疗前,且观察组患者明显高于对照组,差异均有统计学意义(P<0.05);观察组患者糖化血红蛋白的达标率明显高于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:伏格列波糖联合维格列汀治疗2型糖尿病的疗效显著,可明显降低患者血糖水平,不良反应少,安全性高。
OBJECTIVE ：To probe into the efficacy and safety of voglibose combined with vildagliptin in treatment of patients with type 2 diabetes. METHODS： 96 patients with type 2 diabetes admitted into Nanyang the First People＇s Hospital from Jun. 2015 to Jun. 2016 were selected to be divided into observation group and control group via the lottery method, with 48 cases in each. The control group was treated with vildagliptin, while the observation group additionally received voglibose based on the control group. The difference of blood glucose, biochemical indexes and incidence of adverse drug reactions of two groups were compared. RESULTS： After treatment, the FPG, 2 hPG, CRP and HbA~ c level of two groups after treatment were significantly lower than those before treatment, and the observation group was lower than those of control group, with statistically significant difference （P 〈 0. 05）. After treatment, the Fins, 2 bins in two groups were significantly higher than those before treatment, and the observation group was higher than those of control group, with statistically significant difference （P 〈 0. 05 ）. In addition, the control rate of glycosylated hemoglobin of observation group was better than that of control group, with statistically significant difference （ P 〈 0. 05 ）. There was no statistical significance between two groups in the incidence of adverse drug reactions（P 〉0. 05）. CONCLUSIONS： The efficacy of voglibose combined with vildagliptin in treatment of patients with type 2 diabetes is significant, which can effectively reduce the blood glucose level of patients with few adverse drug reactions and high safety.
作者
龚如燕
牛道平
杨庆平
GONG Ruyan NIU Daoping YANG Qingping(Dept. of Venous Allocation Center, Nanyang the First People＇ s Hospital, Henan Nanyang 473000, China Dept. of Endocrinology, Nanyang the First People＇s Hospital, Henan Nanyang 473000, China)
出处
《中国医院用药评价与分析》
2017年第4期516-517,520,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
